

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
14 June 2007 (14.06.2007)

PCT

(10) International Publication Number
WO 2007/067615 A3

(51) International Patent Classification:

C07D 285/10 (2006.01) A61K 31/433 (2006.01)
C07D 417/04 (2006.01) A61P 3/10 (2006.01)
C07D 417/10 (2006.01)

(21) International Application Number:

PCT/US2006/046545

(22) International Filing Date:

6 December 2006 (06.12.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/748,573 8 December 2005 (08.12.2005) US

(71) Applicant (for all designated States except AT, US): NOVARTIS AG [CH/CH]; Lichtstasse 35, 4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GmbH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BARNES, David** [US/US]; 237 Varick Road, Waban, Massachusetts 02468 (US). **BEBERNITZ, Gregory Raymond** [US/US]; 24 Lanes End, Stow, Massachusetts 01775 (US). **COPPOLA, Gary Mark** [US/US]; 18 Aldersgate Circle, Budd Lake, New Jersey 07828 (US). **NAKAJIMA, Katsumasa** [JP/US]; 19 Nassau Drive, Winchester, Massachusetts 01890 (US). **STAMS, Travis** [US/US]; 23 Robinwood Lane, Stow, Massachusetts 01775 (US). **TOPIOL, Sidney Wolf** [US/US]; 15 Lafayette Place, Fair Lawn, New Jersey 07410 (US). **VEDANANDA, Thalaththani Ralalage** [US/US]; 4 Cox Lane, Shrewsbury, Massachusetts 01545 (US). **WAREING, James Richard** [US/US]; 9 Cricket Court, Stow, Massachusetts 01775 (US).

(74) Agent: **FERRARO, Gregory D.**; NOVARTIS, Corporate Intellectual Property, One Health Plaza, East Hanover, NJ 07936-1080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:


— with international search report

(88) Date of publication of the international search report:

15 November 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS



(I)

(57) Abstract: Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or

treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer (such as prostate or breast cancer), osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.